Oncotarget

Research Papers:

Development and validation of a machine learning-based predictive model to improve the prediction of inguinal status of anal cancer patients: A preliminary report

Berardino De Bari _, Mauro Vallati, Roberto Gatta, Laëtitia Lestrade, Stefania Manfrida, Christian Carrie and Vincenzo Valentini

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:108509-108521. https://doi.org/10.18632/oncotarget.10749

Metrics: PDF 1705 views  |   HTML 2394 views  |   ?  


Abstract

Berardino De Bari1, Mauro Vallati2, Roberto Gatta3, Laëtitia Lestrade4,5, Stefania Manfrida3, Christian Carrie4, Vincenzo Valentini3

1Radiation Oncology Department, Centre Hospitalier Universitaire Vaudois-CHUV, Lausanne, Switzerland

2University of Huddersfield, School of Computing and Engineering, Huddersfield, UK

3Radiation Oncology Department, Catholic University of Sacred Heart, Rome, Italy

4Service de Radiothérapie, Léon Bérard Cancer Center, Lyon, France

5Radiation Oncology Department, Hôpitaux universitaires de Genève-HUG, Geneva, Switzerland

Correspondence to:

Berardino De Bari, email: [email protected]

Keywords: anal canal cancer, radiochemotherapy, prophylactic inguinal irradiation, machine learning, predicitive models

Received: May 30, 2016     Accepted: July 07, 2016     Published: July 21, 2016

ABSTRACT

Introduction: The role of prophylactic inguinal irradiation (PII) in the treatment of anal cancer patients is controversial. We developped an innovative algorithm based on the Machine Learning (ML) allowing the tailoring of the prescription of PII.

Results: Once verified on the independent testing set, J48 showed the better performances, with specificity, sensitivity, and accuracy rates in predicting relapsing patients of 86.4%, 50.0% and 83.1% respectively (vs 36.5%, 90.4% and 80.25%, respectively, for LR).

Methods: We classified 194 anal cancer patients with Logistic Regression (LR) and other 3 ML techniques based on decision trees (J48, Random Tree and Random Forest), using a large set of clinical and therapeutic variables. We tested obtained ML algorithms on an independent testing set of 65 anal cancer patients. TRIPOD (Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis) methodology was used for the development, the Quality Assurance and the description of the experimental procedures.

Conclusion: In an internationally approved quality assurance framework, ML seems promising in predicting the outcome of patients that would benefit or not of the PII. Once confirmed in larger and/or multi-centric databases, ML could support the physician in tailoring the treatment and in deciding if deliver or not the PII.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 10749